. 2019 Sep 18;19:930. doi: 10.1186/s12885-019-5967-8

Table 1.

Definition of AML risk classification

Risk	Cytogenetic	Molecular abnormality
Favorable	Core binding factor: inv.(16) or t(16;16) or t(8;21) t(15;17)	Normal cytogenetic: NPM1 mutation in the absence of LT3-ITD, or isolated biallelic CEBPA mutation
Intermediate	Normal cytogenetic + 8 alone t(9;11) Other non-defined
Poor	Complex (≥3 clonal chromosomal abnormalities) Monosomal karyotype −5, 5q-, −7, 7q- 11q23 - non t(9;11) inv.(3), t(3;3) t(6;9) t(9;22)	Normal cytogenetic: with FLT3-ITD mutation6, TP53 mutation

Risk

Cytogenetic

Molecular abnormality

Favorable

Core binding factor: inv.(16) or t(16;16) or t(8;21)

t(15;17)

Normal cytogenetic:

NPM1 mutation in the absence of LT3-ITD,

or isolated biallelic CEBPA mutation

Intermediate

Normal cytogenetic

+ 8 alone

t(9;11)

Other non-defined

Poor

Complex (≥3 clonal chromosomal abnormalities)

Monosomal karyotype

−5, 5q-, −7, 7q-

11q23 - non t(9;11)

inv.(3), t(3;3)

t(6;9)

t(9;22)

Normal cytogenetic:

with FLT3-ITD mutation6,

TP53 mutation